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Abstract
Background: Cystic Fibrosis (CF) is caused by,1,900 mutations in the CF transmembrane conductance regulator (CFTR) gene
encoding for a cAMP-regulated chloride (Cl2) channel expressed in several epithelia. Clinical features are dominated by
respiratory symptoms, but there is variable organ involvement thus causing diagnostic dilemmas, especially for non-classic
cases.
Methodology/Principal Findings: To further establish measurement of CFTR function as a sensitive and robust biomarker
for diagnosis and prognosis of CF, we herein assessed cholinergic and cAMP-CFTR-mediated Cl2 secretion in 524 freshly
excised rectal biopsies from 118 individuals, including patients with confirmed CF clinical diagnosis (n = 51), individuals with
clinical CF suspicion (n = 49) and age-matched non-CF controls (n = 18). Conclusive measurements were obtained for 96% of
cases. Patients with ‘‘Classic CF’’, presenting earlier onset of symptoms, pancreatic insufficiency, severe lung disease and low
Shwachman-Kulczycki scores were found to lack CFTR-mediated Cl2 secretion (,5%). Individuals with milder CF disease
presented residual CFTR-mediated Cl2 secretion (10–57%) and non-CF controls show CFTR-mediated Cl2 secretion $30–
35% and data evidenced good correlations with various clinical parameters. Finally, comparison of these values with those
in ‘‘CF suspicion’’ individuals allowed to confirm CF in 16/49 individuals (33%) and exclude it in 28/49 (57%). Statistical
discriminant analyses showed that colonic measurements of CFTR-mediated Cl2 secretion are the best discriminator among
Classic/Non-Classic CF and non-CF groups.
Conclusions/Significance: Determination of CFTR-mediated Cl2 secretion in rectal biopsies is demonstrated here to be
a sensitive, reproducible and robust predictive biomarker for the diagnosis and prognosis of CF. The method also has very
high potential for (pre-)clinical trials of CFTR-modulator therapies.
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Introduction
Cystic Fibrosis (CF), the most common severe autosomal
recessive disease in Caucasians, is caused by mutations in the CF
transmembrane conductance regulator (CFTR) gene [1–3] which encodes
a cAMP-regulated chloride (Cl2) channel expressed at the apical
membrane of epithelial cells to control salt and water transport [4].
Clinically, CF is characterized by multiple manifestations in
different organs, but is dominated by the respiratory disease, the
main cause of morbidity and mortality. Airway obstruction by
thick mucus and chronic infections, especially by Pseudomonas
aeruginosa (Pa), eventually lead to impairment of respiratory
function [5]. Other CF symptoms include pancreatic insufficiency,
intestinal obstruction, elevated sweat electrolytes and male in-
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fertility [6]. About 1,900 CFTR mutations were reported, but one
single mutation (F508del), associated with severe CF, accounts for
,70% of CF chromosomes worldwide [6]. Despite impressive
advances in our understanding of the molecular basis of CF, life
expectancy and quality of life for CF patients are still limited [5].
For the vast majority of patients, the diagnosis of classic forms of
CF is established early in life and suggested by one or more
characteristic clinical features, a history of CF in a sibling or, more
recently, by a positive newborn screening result [7,8]. Such
diagnosis is usually supported by evidence of CFTR dysfunction
through identification of two CF-disease causing mutations, two
abnormal sweat-Cl2tests ($60 mEq/L), and/or distinctive trans-
epithelial nasal potential difference (NPD) measurements [7,8].
However, depending on the ethnic background of the popula-
tions tested [9] there is a fraction of patients escaping such
diagnosis criteria by presenting ‘‘non-classic’’ symptoms, i.e.,
milder disease and often inconclusive evidence of CFTR
dysfunction from the available diagnostic tools [10,11]. For such
individuals with clinical phenotypes not fully meeting the CF
diagnosis criteria it is also difficult to exclude CF. These are usually
described as ‘‘CFTR-opathies’’ [12] or CFTR-related disorders
(CFTR-RD) [13,14]. Moreover, the recently implemented exten-
sive newborn screening programs identify increasing numbers of
asymptomatic CF patients merely identified by elevated serum
concentrations of immunoreactive trypsinogen (IRT), posing new
challenges to the CF diagnosis paradigm [8,15,16], especially
when associated with borderline sweat [Cl2] and/or inconclusive
CFTR genotypes [10,11,15,16]. To confirm/exclude a CF di-
agnosis in such increasing numbers of individuals, besides close
clinical follow-up, further laboratory support is required [16], in
particular, there is a need for robust methods relying on the
functional assessment of CFTR.
Assessment of CFTR (dys)function in native colonic epithelia ex
vivo, as we previously reported, constitutes a good approach to this
end [17,18]. However, since those data were reported, other
groups have investigated the abnormalities in electrogenic Cl2
secretion in the intestinal epithelium of CF patients using Ussing
chamber measurements by different protocols [19–21]. Unfortu-
nately, the final composite parameter used by some results from
a combination of experimental readouts not all relying on direct
measurement of CFTR-mediated Cl2 secretion, thus leading to
conflicting results and precluding good correlations with clinical
symptoms [19–21].
Since our previous results have established that quantification of
rectal CFTR-mediated Cl2 secretion is a sensitive test for the
diagnosis and prognosis of CF disease [18], hereunder we applied
it to the largest cohort of CF patients and highest number of rectal
biopsies ever assessed in a single study analyzing CFTR-mediated
Cl2 secretion in native tissue ex vivo to evaluate its robustness as
a diagnosis/prognosis biomarker. Our current data demonstrate
significant correlations with CF clinical symptoms, evidencing the
value of this method as a superior laboratory tool to support
clinical practice. Furthermore, here we also applied this technique
to individuals with clinical suspicion of CF to confirm/exclude
a CF diagnosis. Through comparison of the values for CFTR-
mediated Cl2 secretion in these individuals to those both of the CF
reference group and of a non-CF control group, we could confirm
CF in 16/49 individuals (33%) and exclude it in 28/49 (57%), and
five remained with inconclusive diagnosis. Finally, using the
Ussing chamber data in statistical discriminant analyses, together
with the clinical outcomes and other laboratory measurements, we
report that colonic measurements of CFTR-mediated Cl2
secretion, alone or in combination with sweat-Cl2 and fecal
elastase E1 (FEE), provides the best tool for a discriminative
diagnosis among patients with Classic CF, Non-Classic CF and
non-CF individuals.
Methods
Ethics Statement and Subjects
Access to human tissues used in this study received approval
from the Research Ethics Committee of the Faculty of Medical
Sciences, State University of Campinas (UniCamp, ref. 503/
2007). Signed informed consent was obtained from all patients (or
parents/tutors, for those ,18 yrs). Altogether 524 freshly excised
rectal biopsies were analysed from 118 Brazilian individuals,
including CF patients with confirmed diagnosis (n = 51), individ-
uals with CF clinical suspicion (n = 49) and age-matched non-CF
controls (n = 18) undergoing biopsing with no CF-related disorders
and agreeing to participate in the study. Conclusive results were
obtained for 113/118 subjects, i.e., 96% of the cases.
Clinical Assessment
Patient data collected included (Table S1): age at diagnosis,
sweat Cl2 values ($2), body mass index (BMI), Shwachman-
Kulczycki (SK) scores and presence of meconium ileus (MI).
Pancreatic sufficiency (PS) was established by Fecal Elastase E1
(FEE) values ($2) of $200 mg/g stool, while FE concentrations
$100 and #200 mg/g were considered moderate pancreatic
insufficiency (PI) and a history of malabsorption together with FEE
values ,100 mg/g determined PI. Different time point measure-
ments (2–4 per individual) of the best annual forced vital capacity
(FVC) and best annual forced expiratory volume in 1 second
(FEV1) were evaluated from individuals .5–6 years of age, and
expressed as a percentage of predicted normal values for sex, age,
and height. Additional clinical features included nasal polyposis,
glucose intolerance, diabetes, osteopenia, osteoporosis, hepatic
involvement and lung pathogens. Criteria for glucose intolerance
and diabetes were as defined by the American Diabetes
Association [22] by performing the 2h-oral 75g-glucose tolerance
test: when glucose levels were 140–199 mg/dL, glucose in-
tolerance was assigned and when above 200 mg/dL diabetes
was considered. Criteria for osteopenia and osteoporosis were as
defined by the T-score for bone mineral density as recommended
by the World Health Organization [23]: osteopenia was assigned
for values between 21.0 and 22.5 and below 22.5 it was
considered osteoporosis. Regarding the ‘‘hepatic involvement’’ we
used previously defined criteria [24] i.e., patients presenting either
hepatic steatosis, biliary lithiasis and also chronic liver disease. In
most cases, liver disease was initially characterized by hepatic
steatosis, and ultimately there was biliary cirrhosis and portal
hypertension [24]. Ultrasound exams were used to confirm these
clinical findings, analyzing liver parenchyma echogenicity and
evidence for portal hypertension [24]. Blood analysis also showed
increased values for liver transaminases and c-glutamil transferase
(.1.5 fold at least for 6 months). Presence of lung pathogens was
defined by the presence in bronchoalveolar lavage (BAL)/sputum
of: Staphylococcus aureus (Sa), Pseudomonas aeruginosa (Pa), Stenotropho-
monas maltophilia (Sm), Burkholderia cepacia (Bc); Achromobacter xylosox-
idans (Ax) or Aspergillus fumigatus (Af) (see Table S1, under column
‘‘Pathogens detected’’).
Measurements of Sweat Cl2
Sweat was collected on to pre-weighed Cl–-free filter paper for
20–30 min. A minimum sweat rate of 1 g/m2 body surface area/
min was required; thus a minimum of 150 mg of sweat was
considered adequate. Values for Cl2 or Na+ concentrations above
160 mmol/l were discarded as not physiological and sweat test
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repeated. Internal quality control procedures were based on the
usage of standard solutions (BioClinTM, Pretoria, South Africa)
and also samples from individuals with negative and positive sweat
tests. The coefficient of variation (CV) was of 15 mmol/l.
Rectal Biopsies Procedure
Superficial 5–6 rectal mucosa specimens were obtained by
biopsy forceps (EndoflexH 3.4 mm, Voerde, Germany) as de-
scribed before [17,18,25,26] (see Methods S1). One biopsy per
individual was histologically analysed to exclude inflammation,
haemorrhage, infection or other tissue damage (Fig.S1).
Ussing Chamber Measurements
Rectal biopsies were analysed in micro-Ussing chambers under
open-circuit conditions as established previously (see Methods S1).
To minimize sample variability, measurements were performed on
2–5 biopsies (Fig.S2) and data averaged to obtain a single value
per individual.
CFTR Genotyping
Following screening of the 6 most common CFTR-disease
causing mutations in the region of Campinas (Brazil) [27–29]:
F508del, G551D, G542X, R1162X, N1303K, R553X, an
extended CFTR mutation search (see Methods S1) was performed
when only one/none mutation was found (Table S2, with both
traditional and standard nomenclatures [30]).
Chemicals and Compounds
All chemicals (highest available purity) were from Sigma-
AldrichH (St Louis, MI, USA) or MerckH (Darmstadt, Germany)
except for culture media (GIBCOH/Invitrogen, Carlsbad, CA,
USA). Fecal Elastase E1 test was from Schebo H Biotech AG
(Giessen, Germany).
Statistics
For statistical analyses the SPSS software/v.19 (Chicago, IL,
USA) was used and a p-value ,0.05 was considered statistically
significant. Unless otherwise stated, data are mean 6 STD (n,
number of individuals studied). Details of the statistical analysis for
Pearson correlations, Chi-square and discriminant analyses are
described under Methods S1.
Results
Subjects Under Study and Overview of Clinical Data
The clinical diagnosis of CF was established based on consensus
clinical criteria [7,8], namely: 1) presence of one or more
characteristic phenotypic features (chronic sinopulmonary disease;
gastrointestinal/nutritional abnormalities; obstructive azoosper-
mia or salt-loss syndrome) and 2) evidence of a CFTR abnormality
(increased sweat [Cl2] (.60 mEq/L) and/or detection of two CF-
disease causing mutations). Using these criteria and the current CF
classification terminology [10], two different sub-groups of CF
patients (n = 51) were established (detailed clinical data in Table
S1): (a) Classic CF patients (n = 46) presenting a severe phenotype
and classic disease manifestations (high sweat-Cl2; PI; nutrition
deficiencies; chronic sinopulmonary disease); and (b) Non-Classic
CF patients (n = 5) with an atypical phenotype and showing
a milder disease (pancreatic sufficiency-PS; adulthood diagnosis;
less serious lung involvement; and at least one organ with CF
phenotype).
A third group included individuals with a clinical suspicion of
CF (n = 49) of which 27% had only one abnormal sweat-Cl2
value; others presented borderline (22%) or normal (20%) sweat-
Cl2 values (see Methods); and 31% had not been tested for sweat-
Cl2 at the time. Most of these individuals (69%) had inconclusive
genetic testing (20% had only one CF-disease causing mutation
identified) and the remainder had not been CFTR-genotyped at
the time (Table S1). Most of them (68%) showed mono-
symptomatic features, including: respiratory symptoms in 29%
(nasal polyps, chronic cough/bronchitis, pneumonia, bronchiec-
tasis or pansinusopathy); 35% had abnormal gastrointestinal signs
(nutrients malabsorption; failure to thrive; hepatobiliary disease;
chronic diarrhoea; recurrent pancreatitis; diabetes and glucose
intolerance; others presented osteopenia/osteoporosis, liver disease
or male infertility. Fourteen percent of these ‘‘CF suspicion’’
individuals presented relatively mild lung disease and nutrition
abnormalities, one presenting GI and another azoospermia. A
group of 9 patients with severe phenotype (both respiratory and
gastrointestinal) were initially included in this CF suspicion group
(18%) due to their recent identification and while waiting for
confirmation of a CF diagnosis (Table S1).
Assessment of CFTR-mediated Cl2 Secretion in Rectal
Biopsies
CFTR-mediated Cl2 secretion was assessed in rectal biopsies
from the above two sub-groups of CF patients (Classic and Non-
Classic CF) as CF reference. As non-CF control group, we also
analysed CFTR function in age-matched individuals undergoing
routine colonoscopy for non-CF related reasons. Finally, measure-
ments were carried out in the CF suspicion individuals to
establish/exclude a CF diagnosis, following comparison with
values from the CF patients and control groups.
As shown previously [17,18,25,26], application of carbachol
(CCH) under basal conditions elicited lumen-positive responses in
CF and lumen-negative in non-CF tissues (Fig.1A, B, C).
Nevertheless, due to variable levels of endogenous prostaglandins,
lumen-positive responses can also be observed in non-CF control
tissues [17,26]. Thus, when CCH was applied for a second time,
now under indomethacin to completely inhibit endogenous cAMP
(and thus CFTR-mediated Cl2 secretion), all tissues presented
lumen-positive responses correspondent to potassium (K+) exiting
the cell (Fig.1A, B, C) [17,26]. Next, when we used 3-isobutyl-1-
methylxantine (IBMX) and forskolin (Fsk) to activate cAMP-
dependent CFTR-mediated Cl2 secretion [17,18] (Isc-IBMX/Fsk),
we observed lumen-negative responses in tissues from individuals
in both the ‘‘non-CF control’’ group (Fig.1A) and ‘‘Non-Classic
CF’’ sub-group (Fig.1B) but lumen-positive responses for those in
the ‘‘Classic CF’’ sub-group (Fig.1C).
Finally, and as previously described [17,18,25,26,31], following
stimulation with CCH in the presence of IBMX/Fsk (Isc-
CCH(IBMX/Fsk)), three different response patterns were observed
and quantified in relation to pre-reagent (IBMX/Fsk) baseline
values: (i) monophasic lumen-negative (Cl–secretory) in tissues
from ‘‘non-CF controls’’, and we quantified such negative peak
(Fig.1A); (ii) monophasic lumen-positive (K+-secretory) in tissues
from the ‘‘Classic CF’’ subgroup, and we determined both peak
and plateau (Fig.1C); and finally (iii) biphasic responses, in the
‘‘Non-Classic CF’’ sub-group, and we determined both positive
and negative peaks (Fig.1B).
Confirmation/Exclusion of a CF Diagnosis and Correlation
with Genotypes
The equivalent evoked-short-circuit currents (DIsc) calculated
for individuals in the ‘‘CF suspicion’’ group (Fig.1D, open squares,
DIsc values in Table S1) were compared with the reference values
Colonic Cl- Secretion as a CF Biomarker
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for the CF (‘‘Classic CF’’ and ‘‘non-Classic CF’’ sub-groups,
Fig.1D black triangles and diamonds, respectively) and control
groups (Fig.1D, black circles). Accordingly, each individual with
a clinical suspicion of CF could be associated with one of these two
groups (n = 44): for those with a lumen-negative response
(Fig.1A, D) a CF diagnosis was excluded and those presenting
only lumen-positive or biphasic responses (Fig.1B, C, D) were
considered as CF. For the remainder five, data were inconclusive
due to unviability of biopsies. Subsequently, sweat Cl2 test and
extended genotyping was performed for all CF-suspicious individ-
uals. Positive sweat Cl2 and two CF-disease causing mutations
were eventually detected in all individuals (except one) with
absence or residual CFTR-mediated Cl2 secretion (see Table S1).
One ‘‘CF suspicion’’ patient with severe CF symptoms and the
F508del/S549R genotype, evidenced very low levels of CFTR
function (,5% normalized to controls). In almost all ‘‘Classical
CF’’ patients, values for CFTR-mediated Cl2 secretion were zero
and, in the very rare cases with residual currents these were always
lower than 5%. In contrast, for the 28 individuals in the ‘‘CF
suspicion’’ group who showed lumen-negative responses, i.e.,
normal CFTR function (Isc-CCH(IBMX/Fsk) =2153.38615.33 mA/
cm2 vs Isc-CCH(IBMX/Fsk) =2162.07619.64 mA/cm2 in the non-
CF control group) we could only detect one CF-causing mutation
(F508del) in one individual (being thus a CF-carrier) and 2 other
mutations in two individuals who were thus compound heterozy-
gous: W1282X/4428insGA and F508del/D1152H, respectively
(Table S1). Based on their clinical characteristics (only obstructive
azoospermia and bronchiectasis), values of CFTR colonic function
(within the normal range) and CFTR genotypes, these two
individuals were thus classified as CFTR-RD and both 4428insGA
and D1152H were regarded as CFTR-RD mutations. However,
the criteria from colon bioelectric measurements do not support per
se the definition of a group of CFTR-RD subjects, as these
individuals have normal colonic CFTR-mediated Cl2 secretion.
Overall, based on CFTR-mediated Cl2 secretion in the colon
and subsequent confirmatory CF diagnostic testing (sweat Cl2,
Figure 1. Results from Ussing chamber measurements in rectal biopsies from 113 individuals. Original recordings of the effects of
cholinergic (CCH, 100 mM) and cAMP-dependent (IBMX, 100 mM and Fsk, 2 mM, basolateral) activation on transepithelial voltage in rectal tissues from
(A) a healthy control presenting CCH lumen-negative responses; (B) a Non-Classic CF patient showing biphasic responses, thus presenting residual
CFTR function; and (C) a Classic CF patient with no detectable Cl2 secretion, presenting only lumen-positive responses. All the experiments were
performed in the presence of Amiloride (Amil, 20 mM, luminal) and Indomethacin (Indo, 10 mM, basolateral). (D) Summary of activated short-circuit
currents (DIsc) for basal CCH (Isc-CCH), IBMX/Fsk (Isc-IBMX/Fsk) and CCH following IBMX/Fsk application (Isc-CCH(IBMX/Fsk)) in rectal biopsies from controls
(lumen-negative, filled circles, n = 18), Non-Classic CF (biphasic, filled diamonds, n = 5), Classic CF (lumen positive, filled triangles, n = 46) and CF
suspicious patients (open squares, n = 44) showing lumen-negative, biphasic and lumen-positive responses. Data represent the mean of the mean
measurements on 2–5 rectal biopsies per individual. Black solid line shows mean DIsc values for each group represented in mA/cm2: Controls (Isc-CCH =
2109.28614.47; Isc-IBMX/Fsk = 255.38611.12; Isc-CCH(IBMX/Fsk) = 2162.07619.64); Non-Classic CF (Isc-CCH = 47.20617.86; Isc-IBMX/Fsk = 216.2762.83; Isc-
CCH(IBMX/Fsk) = 221.6468.01); Classic CF (Isc-CCH = 30.1362.66; Isc-IBMX/Fsk = 11.3060.78; Isc-CCH(IBMX/Fsk) = 27.1762.22); and CF suspicious with similar DIsc
distribution.
doi:10.1371/journal.pone.0047708.g001
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CFTR genotypes and clinical outcomes (data on Table S1-b), we
could classify the individuals in the ‘‘CF suspicion:’’ group (n = 49)
as: Classic CF (n = 9), Non-Classic CF (n = 7), CFTR-RD (n = 2)
and Non-CF (n = 26). As to the 5 individuals showing inconclusive
Ussing chamber measurements, one individual had one CF-
disease causing mutation (G542X) and two individuals had RD-
related mutations (V562I and G576A). As we could not confirm/
exclude CF in these 5 individuals, they were not included in the
hereunder correlations.
Functional classification of rarer mutations also results from
these analyses, namely (Table S1): 3120+1G.A as class I (2
siblings with 3120+1G.A/R1066C, absence of CFTR-function
and severe phenotypes); 1716+18672A.G as class V (2 other
siblings with F508del/1716+18672A.G, residual CFTR function
228–34%- and mild CF); I618T as class IV (in a patient with
G542X/I618T, 37% CFTR function and mild disease); and
L206W as class IV or CFTR-RD mutation (in a patient with
F508del/L206W and the highest CFTR function257%- and very
mild disease).
Correlation between CFTR-mediated Cl2 Secretion and
Clinical Outcomes
In order to assess the value of CFTR-mediated Cl2 secretion in
rectal biopsies as a predictive tool for CF, we attempted to
statistically correlate these values with the accepted CF-charac-
teristic parameters (Table 1, see also Methods S1), namely: sweat
[Cl2] (Fig.2A, S3A); FEE (Fig.2B, S3B); BMI (Fig.2C, S3C, S4A);
and age at diagnosis (Fig.3A, S3D). For the correlations involving
SK scores (Fig.3B, S3E, S4B) and FEV1 (Fig.3C, S3F, S4C), we
subdivided patients into 4 age-groups (in years): 0–9; 10–19; 20–
29; and $30, since these parameters have been shown to decline
with age [32].
Our data (Fig.2, 3, S3, S4, Tables 1, S3) show high correlations
between CFTR-mediated Cl2 secretion values and these param-
eters describing CF phenotypes. Indeed, patients with absence/
very low CFTR-mediated Cl2 secretion (#5%) had higher sweat-
Cl2 values (114.2362.33 mmol/l), lower FEE concentrations
(9.0862.04 mg/g), earlier age at diagnosis (2.760.6 yrs), lower SK
scores (mean1 = 7163, mean2 = 6963; mean3 = 5662;
mean4 = 5868), and lower FEV1 (mean1 = 7766; mean2 = 7265;
mean3 = 5565; mean4 = 49613) than individuals with normal
values of CFTR-mediated Cl2 secretion. Moreover, CF patients
Table 1. Correlations between clinical outcomes and CFTR-
mediated Isc in rectal biopsies.






Sweat Chloride +0.495 3.4161027 +0.677 4.73610214
Fecal Elastase E1 20.721 6.83610214 20.770 1.10610216
Age at Diagnosis 20.728 1.34610212 20.713 6.18610212
BMI 20.169 0.101 20.226 0.028
BMI - Age at study 20.104 0.319 20.121 0.244
SK Score 20.274 0.009 20.362 4.5961024
SK Score - Age at
study
20.302 0.004 20.411 6.4461025
FEV1 20.205 0.071 20.240 0.035
FEV1 - Age at study 20.251 0.028 20.301 0.008
NOTE: Pearson coefficients (r) and p-values showing statistical correlations
(p,0.05) are highlighted (n = 95).
doi:10.1371/journal.pone.0047708.t001
Figure 2. Correlations between CF laboratory measurements
and CCH-induced short circuit currents following IBMX/Fsk
application (Isc-CCH(IBMX/Fsk)). Scatter-plot summarizing the distribu-
tion of Isc-CCH(IBMX/Fsk) against (A) sweat [Cl
2] (mmol/l); (B) FEE
concentrations (mg/g of stools); and (C) BMI for all individuals included
in the study showing conclusive results (n = 113) and classified
according to CF Clinical Diagnosis Consensus Guidelines as: Classic CF
(filled triangles, n = 55); Non-Classic CF (filled diamonds, n = 12); CFTR-
RD (star, n = 2); and non-CF (open circles, n = 26). Vertical dashed black
line represents subtraction of one SD of the mean value calculated for
Isc-CCH (IBMX/Fsk) (DIsc =278.77 mA/cm2) in non-CF controls (‘‘grey zone’’).
Vertical dotted grey line represents addition of one SD of the mean
value calculated for Isc-CCH(IBMX/Fsk) (DIsc =239.55 mA/cm2) in reference
sub-group of Non-Classic CF patients.
doi:10.1371/journal.pone.0047708.g002
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with residual values of CFTR-mediated Cl2 secretion had
intermediate values in those parameters, namely: sweat-Cl2 values
(109.8068.34 mmol/l); FEE concentrations (444.57678.05 mg/
g), age at diagnosis (19.663.4 yrs), SK scores (mean1 = 90;
mean2 = 77614; mean3 = 63612; mean4 = 5567); and FEV1
(mean1 = n.a.; mean2 = 82626; mean3 = 6169; mean4 = 6063).
Moreover, patients with classic CF and #5% CFTR-mediated
Cl2 secretion consistently presented faster decline rates of
pulmonary function [32,33] (Fig.3-D, dashed line), than Non-
Classic CF patients retaining residual (Fig.3-D, dotted line) or
normal CFTR functions (Fig.3-D, solid line, p= 0.001 by Kruskal-
Wallis test). Regarding BMI (Fig.2-C, Table 1), only a modest
trend was observed for lower BMI values in CF patients with
absence of Cl2 secretion, not related to age differences (Fig.S4-A,
S3-C, Table 1).
Next, we analysed the distribution of other clinical features (MI,
nasal polyposis, diabetes/GI, osteopenia/osteoporosis) and also
presence of lung pathogens in the three groups under study.
Significant differences (Table 2) were found between the groups
under study for the distribution of lung pathogens (p= 1.7561026,
88% of CF patients with pathogens), with predominance of Pa,
and MI (p= 0.0015, 24% of CF patients with MI).
Altogether, these data indicate that our approach to measure
the level of CFTR (dys)function in rectal biopsies provides data
evidencing good correlation with the CF severity.
Evaluation of the Best Tool for Discriminating CF Patients
from Non-CF Individuals
Following the above findings, we attempted to establish a CF
diagnosis tool which could also serve for disease prognosis. We
thus used a stepwise discriminant analysis to evaluate which one(s)
among the clinical and laboratory measurements available (sweat-
Cl2; FEE; BMI; SK score; FEV1; Isc-IBMX/Fsk; and Isc-CCH(IBMX/
Fsk)), constitutes the best discriminator factor between patients with
Classic and Non-Classic CF and also between these groups and
non-CF individuals (see Methods). As shown in Fig.4, discriminant
function 1 (x-axis) corresponding to CFTR-mediated Cl2 secre-
tion measurements in rectal biopsies under CCH (Isc-CCH(IBMX/
Fsk)) is the best option to explain the differences between the three
groups in 90.4% of cases (Tables S4, S5). Additionally, FEE
concentration and sweat-Cl2 correspond to discriminant function
2 (y-axis) enabling separation of an additional ,6% of the
remainder individuals (Tables S4, S5). Notwithstanding, four Non-
Classic CF patients were still misclassified as Classic CF (Fig.4,
black diamonds with dotted circles). Furthermore, to translate this
discriminant analyses into a diagnosis algorithm, we have obtained
its respective Fisher’s linear classification functions as:
Classic CF= 0.317(Sweat Chloride) +0.005(Fecal Elastase)
+0.012(Isc-CCH(IBMX/Fsk)) –18.909.
Non-Classic CF= 0.338(Sweat Chloride) +0.028(Fecal Elas-
tase) 20.015(Isc-CCH(IBMX/Fsk)) –28.485.
Non- CF= 0.202(Sweat Chloride) +0.026(Fecal Elastase)
20.102(Isc-CCH(IBMX/Fsk)) –23.414.
Figure 3. Correlations between CF clinical features and CCH-induced short circuit currents following IBMX/Fsk application (Isc-
CCH(IBMX/Fsk)). Scatter-plot summarizing the distribution of Isc-CCH(IBMX/Fsk) against (A) age at diagnosis (in years); (B) SK clinical scores distributed by
groups of ages; and (C) FEV1 distributed by groups of ages. Other details as in Fig.2. (D) Mixed regression model for decline rates in FEV1 vs. Age
(n = 232 measurements) for Classic CF (y = 93.15–0.73x), Non-Classic CF (y = 92.23–0.52x), and Non-CF (y = 96.86–0.346) groups, as described [32,33].
doi:10.1371/journal.pone.0047708.g003
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These allow classification of a new CF suspicion case by
replacing in these 3 equations the values from laboratory
measurements obtained for a given individual. The function
giving the highest value will correspond to the CF classification
group best describing the individual.
Discussion
The wide spectrum of CF phenotypes, high variability of CF
lung disease, the uncertain (dys)function of many rare CFTR
mutations together with increasing numbers of asymptomatic
patients identified in recent newborn CF screens, have posed
major challenges to clinicians for the establishment of CF
diagnoses and prognosis [8,10,11]. Such hurdles make it difficult
for caregivers to provide adequate genetic counselling and medical
care, risking worsening of symptoms and organ damage.
Good Correlations between CFTR-mediated Cl2
Secretion and CF Parameters
To evaluate the robustness of colonic CFTR-mediated Cl2
secretion as a diagnosis/prognosis biomarker and thus help
overcoming such difficulties, we assessed CFTR (dys)function ex
vivo in 524 rectal biopsies from 118 individuals, including the
largest cohort of CF patients ever analysed by this approach
(n = 51), a non-CF (control) group (n = 18) and individuals with
clinical CF suspicion to confirm/exclude a CF diagnosis (n = 49).
The functional data, demonstrating good correlations with most
CF-defining parameters, have also provided key information to
adjust the clinical judgment of a CF diagnosis and prognosis.
Our approach consists in direct measurements of colonic CFTR
function assessed through both cAMP-dependent and cholinergic
Cl2 secretion which, as previously shown [25,26,31], are strictly
dependent on the presence of functional CFTR. Our data here
show that CFTR-mediated Cl2 secretion is absent or present at
almost undetectable levels (,5%) in 244 biopsies from patients
with classic forms of CF (Fig.1, Table S1), as defined by consensus
criteria [7,8,10] including: early age at diagnosis (2.760.6 yrs),
very high sweat-Cl2 (114.2362.33 mmol/l) and PI
(9.0862.04 mg/g) (Fig.2, 3, S3, S4, Table S3). This group of
Classic CF patients also presented other severe CF symptoms (as
defined in Methods), like MI (29%), associated diabetes and/or GI
(27%), lung pathogens (87%) and also hepatic involvement (29%)
(Tables 2, S1). In contrast, a group of patients with milder
symptoms, classified as Non-Classic CF by established guidelines
[7,8,10], evidenced residual CFTR-mediated Cl2 secretion (10 to
57%), consistently with our previous data [18]. Indeed, most of
patients in this group were diagnosed at an older age
(19.663.4 yrs) and were PS (444.57678.05 mg/g) (Fig.2, 3, S3,
Table 2. Distribution of clinical features among the 3 groups of individuals analysed here: Classic CF; Non-Classic CF and Non-CF.
CF Clinical Diagnosis
Classic CF Non Classic CF Non-CF Total (n)
Isc-CCH(IBMX/










Pa 7 3 1 11
Pa with
other pathogens
21 5 0 26
Other pathogens 20 3 2 25
Negative 2 0 7 9
n.a. 5 1 18 24
Meconium Ileus (p=0.0015) Positive 16 0 0 16
Negative 39 12 26 77
n.a. 0 0 2 2
Nasal Polyposis (p= 0.591) Positive 10 4 6 20
Negative 44 8 20 72
n.a. 1 0 2 3
Glucose Intolerance (GI)/
Diabetes (p=0.303)
GI 5 1 0 6
Diabetes 5 2 2 9
GI/Diabetes 5 0 0 5
Negative 39 9 23 71
n.a. 1 0 3 4
Osteopenia/Osteoporosis
(p= 0.511)
Osteopenia 2 0 2 4
Osteoporosis 6 3 2 11
Negative 46 9 22 77
n.a. 1 0 2 3
NOTE: n.a., Not analysed. p-values showing statistical differences among groups under study (p,0.05) are highlighted (n = 95). GI, Glucose Intolerance.
doi:10.1371/journal.pone.0047708.t002
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S4, Table S3). Additionally, by stratifying patients into four
different age groups, our functional data also showed good
correlations with lung function (FEV1) and SK scores, where
patients with highest values evidenced residual colonic CFTR-
mediated Cl2 secretion (Table 1, r=20.301 and 20.411,
respectively).
Comparison with Other Bioelectric Methods
By applying a different Ussing chamber protocol to bioelectric
measurements in rectal biopsies, other authors used an overall
parameter resulting from a combination of different readouts,
some relying on indirect activation of CFTR and thereof proposed
a cut-off value [20]. Yet, application of such protocol in another
study reported a classic CF patient evidencing readout values
higher than the cut-off [21]. So, it is our conviction that such cut-
off value cannot be clearly established for usage among different
laboratories [20,21]. Moreover, several technical aspects differed
between the current and such protocol. Firstly, here we use
bicarbonate (HCO32)-free buffer solutions to exclude a possible
contribution of electrogenic HCO32 secretion to lumen-negative
Vte/Isc [18,34,35]. Secondly, our measurements evidence stable
baselines in contrast to the drifting baselines reported in those
studies where agonist responses have to be determined from
estimated baselines [21]. Thirdly, our readout is based on direct
CFTR-mediated Cl2 secretion under complete inhibition of
endogenous cAMP [17,18,25,26,31,35], instead of complex bio-
electric responses involving two different Ca2+-dependent agonists
and an anion-transporter inhibitor following incomplete prosta-
glandin inhibition [19–21]. Our protocol has the major advantage
of using continuous perfusion which allows for pairwise examina-
tion of agonists. Altogether, these characteristics, together with the
demonstration of its extreme sensitiveness (accurate calculation of
CFTR activity down to ,5%, Table S1), and high reproducibility
(very stable baseline currents during the .2 h course of the
experiments and similar recordings in different biopsies from the
same individual taken on the same day Fig.S2) make the current
approach a superior contribution for CF diagnosis and prognosis
(Fig.4).
Another technique to support a CF diagnosis is NPD
measurements. The outcome of this approach, however, relies
on a composite score including both ENaC- and CFTR-mediated
responses [36–41], where two abnormal NPD recordings on
separate days evidence CFTR dysfunction [7,8]. The technique,
however, has variable applicability for adults and children [41].
Moreover, this in vivo procedure requires patient immobilization
and sedation (for children ,6 yrs) for at leastK h [41], while the
rectal biopsing only takes ,10 min allowing for multiple ex vivo
measurements of different samples from the same individual and
lead to conclusive results (96% here) for a highest percentage of
individuals than NPD (91% [41]). Moreover, NPD values
considerably overlap among CF patients, carriers and non-CF
controls [37–39,41]. This may be due to the fact that NPD is not
a truly quantitative measurement but relies on the pure
measurement of voltages.
Validation as a Biomarker for CF Diagnosis/Prognosis
Importantly, we show here how assessment of colonic CFTR
function was a key tool to exclude CF in 28 individuals (2 of
classified as CFTR-RD patients). In fact, despite that the clinical
features of these individuals suggested CF, both genotyping and
sweat test were inconclusive (Table S1). This leads us to conclude
of the importance of this approach for patients in the ‘‘grey’’ zone
(Fig.2, 3) for the establishment/exclusion of a final diagnosis of CF
or CFTR-RD.
Interestingly, our data are also highly informative to correlate
CFTR function with CFTR genotypes (Fig.5). For instance, we
were able to detect very low function (,5% CFTR function vs
non-CF controls) in a patient bearing S549R, recently described as
Figure 4. Distribution showing the relative position of each individual in study according to the scores obtained by discriminant
analysis (territorial map). Analysis performed for individuals having complete information about Isc-CCH(IBMX/Fsk), FEE concentration in stools and
sweat-Cl2 (n = 75): Classic CF (filled triangles, n = 47); Non-Classic CF (filled diamonds, n = 11); and non-CF (open circles, n = 17). Misclassified cases are
marked with dotted circles. Grey squares represent the group centroids and grey lines the barriers between each group. * according to consensus
criteria [7,8,10].
doi:10.1371/journal.pone.0047708.g004
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Class III [42], whereas significant CFTR-mediated Cl2 secretion
was found in two patients bearing 4428insGA and D1152H (84
and 64%, respectively). Thus, we classify the former here as CF-
disease causing and the two latter as CF-RD mutations.
In the present study, we have also used a statistical discriminant
analysis to identify which clinical and functional parameter(s)
better reflects the differences among Classic CF, Non-Classic CF
and Non-CF groups for prognosis. Results show that Isc-CCH(IBMX/
Fsk) measurements are more discriminative than Isc-IBMX/Fsk,
evidencing the highest discriminant power (90.4%) among the
three groups studied. The second and third parameters with
higher discriminant power are FEE and sweat-Cl2 concentration,
respectively. Using such analysis (Fig.4), one can for example
predict that individuals in the ‘‘Non-Classic CF’’ group with values
lying closer to the ‘‘Non-CF’’ cluster, have better prognosis than
those with values closer to the ‘‘Classic CF’’ cluster. In fact, the
only four cases with ‘‘Non-Classic CF’’ which were misclassified as
‘‘Classic CF’’ by this analysis, correspond to individuals with
moderate PI and/or low levels of CFTR function. It may, thus be
expected that these four patients develop severe CF earlier than
most Non-Classic ones. Interestingly, and corroborating such
prediction among these four, there is a 19-year old patient with the
F508del/G85E genotype, moderate PI (FEE = 103.89 mg/g) and
,12% of CFTR function (Fig.S2-C, Table S1) who recently (last
1K yr) started to progress from a relatively mild to moderate-
severe lung disease, with five pulmonary exacerbations plus
surgery to remove nasal polyps associated with a strong sinusitis.
Recently, we demonstrated that the current approach may be
used in pre-clinical assessment of therapeutic compounds efficacy
directly on native tissues [43] and similarly it may be used to
identify CF patients (and CFTR mutations) who will respond to
innovative therapeutic strategies, namely those aimed at increasing
the residual CFTR activity and already approved for clinical use
for other mutations towards a predictive personalized-medicine
approach [18,43–47]. For example, the patient with S549R could
be tested ex vivo for the correction with the FDA-approved
potentiator Ivacaftor, as suggested by the in vitro data [42].
Moreover, based on our data showing good correlations of CFTR-
mediated Cl2 secretion with absolute FEV1 values and FEV1
decline rate (Fig. 3), as well as taking into account our discriminant
analyses (Fig.4) demonstrating that CFTR-mediated Cl2 has the
highest discriminant power (90.4%) to distinguish among Classic
CF, Non-Classic CF and Non-CF groups, we propose that colonic
CFTR-mediated Cl2 secretion, perhaps together with sweat-Cl2,
may be the best biomarker in clinical trials aimed at modulating
CFTR [44,48].
What is the Functional CFTR Threshold to Avoid CF?
Finally, in an attempt to further answer the old question ‘‘how
much functional CFTR would be enough to avoid CF?’’ [49] we
have put together the current and previous findings, including
those concerning mRNA levels, to establish the threshold for CF
[18,50–52] (Fig.5). Indeed, we previously showed that ,5% of
normal CFTR transcripts (relative to non-CF individuals) is sufficient
to attenuate CF severity [50–52]. From our current and previous
data, we propose that CFTR values above,10% of normal CFTR
function are required for a better CF prognosis since all ‘‘Non-
Classical CF’’ patients had values for CFTR-mediated Cl2
secretion higher than 10%. Indeed, CF patients with CFTR
function below 10% evidence more severe CF (Table S1).
Moreover, as non-CF controls and individuals for whom a CF
diagnosis was discarded show CFTR-mediated Cl2 secretion
$30–35%, as before [18], we propose to set at 30% the threshold
of CFTR function which is necessary to reach to avoid any form of
CF disease.
In conclusion, our current approach to measure CFTR-
mediated Cl2 secretion in rectal biopsies is demonstrated here
to be a sensitive, reproducible and robust predictive biomarker for
the diagnosis/prognosis of CF. Moreover this method has very
high potential to be used as endpoint for (pre-)clinical trials of
innovative therapeutic approaches involving CFTR-modulators.
Supporting Information
Figure S1 Histological evaluation of rectal biopsies by
Hematoxilin-Eosin (HE) and Masson’s Tricome stain-
Figure 5. Association of CF clinical phenotypes with the levels of normal CFTR mRNA transcripts, CFTR function (as percentage of
maximal CFTR activation normalized to control group) and CFTR mutations (grouped by functional classes of mutations) with
examples found in this study. Indicated values are speculative. *D1152H may belong either to CFTR-RD or CFTR-disease causing mutations.
CBAVD, Congenital Bilateral Absence of the Vas Deferens; ABPA, Allergic Bronchopulmonary Aspergillosis; PS, Pancreatic Sufficiency; PI, Pancreatic
Insufficiency; MI, Meconium Ileus; DIOS, Distal Intestinal Obstruction Syndrome.
doi:10.1371/journal.pone.0047708.g005
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ings in control (transversal cut), Non-CF (longitudinal cut),
Classical CF (transversal cut) and Non-Classical CF (longitudinal
cut) showing a healthy epithelia, namely no fibrotic processes were
observed and some biopsies presented inflammatory processes,
independent of being CF or not. In HE stained sections we
observe nuclei in blue and cytoplasm in pink to red. For Tricome’s
Masson we observe collagen in blue, nuclei black, and muscle and
cytoplasm in red. Black scale bar represents 250 mM.
(DOCX)
Figure S2 Original recordings of transepithelial voltage
(Vte) measurements in Ussing chambers obtained in 3–4
rectal biopsies from the same individual evidencing the
high reproducibility of the method. Rectal biopsies from (A)
Non-CF individual showing large cholinergic (carbachol, CCH,
100 mM, basolateral) and cAMP-dependent (3-isobutyl-1-methyl-
xantine, IBMX, 100 mM, and forskolin, Fsk, 2 mM, basolateral)
Chloride (Cl2) secretion (lumen-negative responses); (B) CF
patient homozygous for F508del-CFTR mutation with absence
of Cl2 secretion (only lumen-positive responses, reflecting
potassium (K+) secretion, were observed); (C) CF patient
(genotype: F508del/G85E-CFTR) showing very little (,12%)
cAMP-dependent Cl2 secretion (biphasic responses observed
upon co-cholinergic stimulation with CCH); and (D) CF patient
(genotype: 3120+1G.A/L206W-CFTR) presenting larger CFTR
residual function (,57%) and milder phenotype than in (C). All
the experiments were performed in the presence of Amiloride
(Amil, 20 mM, luminal) and Indomethacin (Indo, 10 mM,
basolateral). Transepithelial resistance (Rte) was determined from
Vte deflections obtained by pulse current injection (0.5 mA).
(DOCX)
Figure S3 Correlations between CF clinical features and
IBMX/Fsk-induced short circuit currents (Isc-IBMX/Fsk).
Scatter-plot summarizing the distribution Isc-IBMX/Fsk against (A)
sweat chloride concentrations (in mmol/l); (B) age at diagnosis (in
years); (C) Body Mass Index distributed by groups of ages; (D)
Fecal Elastase E1 concentrations (in mg/g of stools); (E) Shwach-
man–Kulczycki clinical scores distributed by groups of ages; and
(F) FEV1 (% of predicted normal values for sex, age, and height)
distributed by groups of ages. Vertical dashed black line represents
subtraction of one standard deviation (STD) of the mean value
calculated for Isc-IBMX/Fsk in non-CF controls (DIsc = 28.18 mA/
cm2). Vertical dashed grey line represents addition of one STD of
the mean value calculated for Isc-IBMX/Fsk in reference sub-group
of Non-Classic CF patients (DIsc = 222.60 mA/cm2). Classic CF
(filled triangles, n = 55); Non-Classic CF (filled diamonds, n = 12);
CFTR-RD (star, n = 2) and Non-CF (open circles, n = 26)
individuals.
(DOCX)
Figure S4 Correlations between CF clinical features and
CCH-induced short circuit currents following IBMX/
Fsk application (Isc-CCH (IBMX/Fsk)). Scatter-plot summarizing
the distribution of Isc-CCH (IBMX/Fsk) against (A) Body Mass Index;
(A) Body Mass Index distributed by groups of ages; (C) Shwach-
man–Kulczycki clinical scores; and (D) forced expiratory volume
in 1 second (FEV1) expressed as a percentage of predicted normal
values for sex, age, and height (% predicted).Vertical dashed black
line represents subtraction of one standard deviation (STD) of the
mean value calculated for CCH induced-DIsc following IBMX/
CCH application (DIsc =278.77 mA/cm2) in non-CF controls.
Vertical dashed grey line represents addition of one STD of the
mean value calculated for CCH stimulated-DIsc following IBMX/
CCH application (DIsc =239.55 mA/cm2) in reference sub-group
of Non-Classic CF patients. Classic CF (filled triangles, n = 55);
Non-Classic CF (filled diamonds, n = 12); CFTR-RD (star, n = 2)
and Non-CF (open circles, n = 26) individuals.
(DOCX)
Table S1 Overview of data for all CF patients in the
reference group (Table S1a) and in the CF-suspicious
group (Table S1b): genotypes, clinical phenotypes and
Ussing chamber measurements, leading to confirma-
tion/exclusion of a CF Diagnosis.
(XLSX)
Table S2 CFTR mutations found in individuals under
study. Gene and protein localization, mutation classifi-
cation and frequency from the present study are
designated. Traditional and HGVS standard nomencla-
ture for CFTR mutations are also indicated.
(DOCX)
Table S3 Mean and standard error of the mean values
for clinical parameters among the 3 groups of individ-
uals analyzed in this study: Classic CF; Non-Classic CF
and Non-CF.
(DOCX)
Table S4 Discriminant Functions: Eigenvalues and
Wilk’s Lambda statistics.
(DOCX)
Table S5 Canonical Discriminant Functions used in the
Analysis.
(DOCX)
Methods S1 Cl- secretion in Rectal Biopsies.
(DOCX)
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